Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13758787 | 1.00 | ALDH1A1 (0.35) | ALDH1A1LMNAPOLBGABRR1SYNJ2 | |
| SCHEMBL12450139 | 0.84 | ALDH1A1 (0.35) | ALDH1A1LMNAPOLBGABRR1 | |
| SCHEMBL13968808 | 0.80 | GABRR1 (0.34) | GABRR1 | |
| SCHEMBL415680 | 0.80 | GABRR1 (0.34) | GABRR1 | |
| SCHEMBL17193807 | 0.79 | — | — | |
| Shikimic Acid SCHEMBL9885028 | 0.79 | GABRR1 (0.36) | GABRR1 | |
| Shikimic Acid SCHEMBL8943144 | 0.79 | GABRR1 (0.36) | GABRR1 | |
| Shikimic Acid SCHEMBL43377 | 0.79 | GABRR1 (0.36) | GABRR1 | |
| Shikimic Acid SCHEMBL13577074 | 0.79 | GABRR1 (0.36) | GABRR1 | |
| Shikimic Acid SCHEMBL12833224 | 0.79 | GABRR1 (0.36) | GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | UNIV WARWICK (GB) | 2020-02-13 | — | — | US | disclosed |
| US-9233263-B2 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2016-01-12 | — | — | US | disclosed |
| US-9233263-B2 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2016-01-12 | — | — | US | disclosed |
| US-20120039828-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | Industrial Framaceutica Cantabria, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20120039828-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | Industrial Framaceutica Cantabria, S.A. (ES) | 2012-02-16 | — | — | US | disclosed |
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2007-02-01 | — | — | US | disclosed |
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. (ES) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070025933-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | ME1, ME2, SI | ALDH1A1 2765/4885LMNA 3635/4885POLB 350/4885 |
| US-20200048183-A1 | ANTIMICROBIAL AGENTS | C3AR1, HCAR3, C5AR1 | ALDH1A1 1104/4885LMNA 2290/4885POLB 3538/4885 |
| US-20120039828-A1 | Photoprotector and/or photoimmunoprotector compositions of the skin and their uses | ME1, ME2, SI | ALDH1A1 2765/4885LMNA 3635/4885POLB 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.